News | October 15, 2007

Medtronic Suspends Distribution of Defibrillation Leads

October 16, 2007 – Medtronic Inc. said in a statement that it has voluntarily suspended worldwide distribution of the Sprint Fidelis family of defibrillation leads because of the potential for lead fractures, and the company recommends that physicians do no perform new implants of the leads (Sprint Fidelis Models: 6930, 6931, 6948, 6949).

The Sprint Fidelis leads are used to deliver therapy in defibrillators only, including Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy – Defibrillators (CRT-Ds). Approximately 268,000 Sprint Fidelis leads have been implanted worldwide. This action does not affect Medtronic pacemaker patients.

Medtronic, its Independent Physician Quality Panel, and Bruce Lindsay, M.D., Professor of Medicine, Director of Cardiac Electrophysiology, Washington University School of Medicine and President of the Heart Rhythm Society (HRS), do not recommend that patients seek prophylactic replacement of Sprint Fidelis leads, as the risks of removal or insertion of another lead exceed the small risk to patients of a lead fracture. Medtronic has provided patient management recommendations that should reduce risks in the affected population and recommends that patients with questions consult their physicians. Information is also available for patients and physicians at www.medtronic.com/fidelis.

This decision is based on a variety of factors that, when viewed together, indicate that suspending distribution is the appropriate action. Based on Medtronic’s extensive performance data, Sprint Fidelis lead viability is trending lower than Medtronic’s Sprint Quattro lead at 30 months (97.7 percent Sprint Fidelis vs. 99.1 percent Sprint Quattro). This difference is not statistically significant; however, if the current lead fracture rates remain constant, it will become so over time. Medtronic believes that given this performance trend and its ability to identify the primary fracture locations, this action is in patients’ best interest.

Lead fractures may present clinically as audible alerts, inappropriate shocks and/or loss of output. Based on current information regarding the 268,000 implanted leads, Medtronic has identified five patient deaths in which a Sprint Fidelis lead fracture may have been a possible or likely contributing factor.

The FDA intends to issue a public statement regarding Medtronic’s decision at www.fda.gov.

In conjunction with Medtronic’s Independent Physician Quality Panel, Medtronic communicated, via letter and direct outreach with more than 13,000 physicians worldwide, the Sprint Fidelis lead performance data and updated patient management recommendations for patients who are implanted with Sprint Fidelis leads. These recommendations include device programming and patient management recommendations that will ensure a patient’s device is set to more effectively monitor for potential problems and provide an audible alert in the event of lead fractures.

Source: Medtronic

For more information: www.medtronic.com/fidelis

Related Content

Feature | Implantable Cardioverter Defibrillator (ICD) | By Dave Fornell, Editor

February 2, 2020 — The U.S. Food and Drug Administration (FDA) has identified a recent recall of the Boston Scientific ...

Home February 02, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

January 8, 2020 — A new study published this week in HeartRhythm, the journal of the Heart Rhythm Society (HRS), found ...

Home January 08, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 8, 2020 — Final results from the UNTOUCHED study of the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System ...

Home May 08, 2020
Home
Feature | Implantable Cardioverter Defibrillator (ICD)

May 8, 2020 — A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable ...

Home May 08, 2020
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 11, 2019 — Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational ...

Home October 11, 2019
Home
News | Implantable Cardioverter Defibrillator (ICD)

September 18, 2019 — Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention ...

Home September 18, 2019
Home
Feature | Implantable Cardioverter Defibrillator (ICD) | Dave Fornell, Editor

This is a brief overview of updates on implantable cardioverter defibrillators (ICD), including new technology ...

Home May 24, 2019
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the ...

Home May 13, 2019
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 9, 2018 — Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable ...

Home August 09, 2018
Home
Feature | Implantable Cardioverter Defibrillator (ICD)

July 11, 2018 — Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and ...

Home July 11, 2018
Home
Subscribe Now